{
    "clinical_study": {
        "@rank": "62268", 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine the effects of selegiline on the subjective and\n      physiological effects of cocaine challenge in chronic crack abusers, and to evaluate\n      clinical safety issues pertaining to selegeline, to cocaine and their interaction in a\n      chronic crack dependent population."
        }, 
        "brief_title": "Infusion Laboratory: Protocol 1 - Selegeline - 2", 
        "condition": "Cocaine-Related Disorders", 
        "condition_browse": {
            "mesh_term": "Cocaine-Related Disorders"
        }, 
        "detailed_description": {
            "textblock": "To develop a medication for the treatment of cocaine addiction using a medical human\n      physio-neuro-psycho-immunology laboratory setting. To characterize this cocaine abusing\n      population on a variety of psychological and physicologically measures over time from\n      withdrawal through pere and post cocaine administration.  To determine the effects of\n      selegeline on the subjective and physiological effects of cocaine challenge in chronic crack\n      abusers.  To evaluate clinical safety issues pertaining to selegeline, to cocaine and their\n      interaction in a chronic crack dependent population."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        M/F, ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the\n        study and sign informed consent.\n\n        Exclusion Criteria:\n\n        Psychiatric disorder that requires medication therapy. History of seizures. Pregnant\n        and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics.\n        Acute hepatitis. Other medical condtions that deem participation to be unsafe."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "47 Years", 
            "minimum_age": "31 Years"
        }, 
        "enrollment": "0", 
        "firstreceived_date": "September 20, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000337", 
            "org_study_id": "NIDA-3-0010-2", 
            "secondary_id": "Y01-3-0010-2"
        }, 
        "intervention": {
            "intervention_name": "Selegiline", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Selegiline"
        }, 
        "lastchanged_date": "November 3, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Los Angeles", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90025"
                }, 
                "name": "Friends Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Infusion Laboratory: Protocol 1 - Selegeline", 
        "overall_official": {
            "affiliation": "Friends Research Institute, Inc.", 
            "last_name": "Walter Ling, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "primary_outcome": [
            {
                "measure": "Degree of drug craving"
            }, 
            {
                "measure": "History, incidence and amount of drug use"
            }, 
            {
                "measure": "Type and severity of stimulant withdrawal symptoms"
            }, 
            {
                "measure": "Population incidence of symptoms of depression, possible organic brain syndrome deficits"
            }, 
            {
                "measure": "Frequency and intensity of drug use and sexual behaviors at risk for HIV"
            }, 
            {
                "measure": "Evidence of change in neurophysiology and brain activity"
            }, 
            {
                "measure": "Evidence of change in subjective responses to cocaine challenge"
            }, 
            {
                "measure": "Clinical physiological response to cocaine challenge - especially adverse effects measures"
            }, 
            {
                "measure": "Degree to which study medication influences changes in #6, 7 & 8 above (possible efficacy measure)"
            }, 
            {
                "measure": "Characterization of study population"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000337"
        }, 
        "source": "National Institute on Drug Abuse (NIDA)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute on Drug Abuse (NIDA)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "November 1994", 
        "study_design": "Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 1996"
    }, 
    "geocoordinates": {
        "Friends Research Institute": "34.052 -118.244"
    }
}